×
Grace Therapeutics Common Stock Net 2014-2024 | GRCE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Grace Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Grace Therapeutics Common Stock Net 2014-2024 | GRCE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Grace Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.6B
Vertex Pharmaceuticals (VRTX)
$126.2B
Bristol Myers Squibb (BMY)
$119.7B
Gilead Sciences (GILD)
$117.5B
Regeneron Pharmaceuticals (REGN)
$90.2B
CSL (CSLLY)
$90B
GSK (GSK)
$73.6B
Argenex SE (ARGX)
$35.5B
Alnylam Pharmaceuticals (ALNY)
$34.7B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$24.5B
Illumina (ILMN)
$23.4B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$16.7B
Incyte (INCY)
$15.5B
Genmab (GMAB)
$14.9B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$11.8B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Revolution Medicines (RVMD)
$10B
QIAGEN (QGEN)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Exact Sciences (EXAS)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.3B
Ascendis Pharma (ASND)
$7.7B